New Perspectives in Clostridium difficile Disease Pathogenesis

Infectious Disease Clinics of North America

Volumn 29, Issue 1, 2015, Pages 1-11

  Monaghan, Tanya M ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Clostridium difficile; Host response; Microbiota; Spore; Virulence factors

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; VIRULENCE FACTOR;

ADAPTIVE IMMUNITY; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE INFECTION; DYSBIOSIS; HUMAN; IN VITRO STUDY; INNATE IMMUNITY; INTESTINE FLORA; NONHUMAN; PATHOGENESIS; PEPTOCLOSTRIDIUM DIFFICILE; PHYLOGENY; REVIEW; SPORE GERMINATION; SPOROGENESIS; CLOSTRIDIUM INFECTIONS; GASTROINTESTINAL TRACT; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MICROBIOLOGY; MICROFLORA; PATHOGENICITY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADAPTIVE IMMUNITY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; GASTROINTESTINAL TRACT; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; MICROBIOTA; VIRULENCE FACTORS;

EID: 84922906286     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2014.11.007     Document Type: Review

References (96)

1. Clements A.C., Magalhaes R.J., Tatem A.J., et al. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 2010, 10:395-404.
2. Best E.L., Freeman J., Wilcox M.H. Models for the study of Clostridium difficile infection. Gut Microbes 2012, 3:145-167.
3. Hutton M.L., Mackin K.E., Chakravorty A., et al. Small animal models for the study of Clostridium difficile disease pathogenesis. FEMS Microbiol Lett 2014, 352:140-149.
4. Elliott B., Chang B.J., Golledge C.L., et al. Clostridium difficile-associated diarrhoea. Intern Med J 2007, 37:561-568.
5. Kelly C.P., Pothoulakis C., LaMont J.T. Clostridium difficile colitis. NEngl J Med 1994, 330:257-262.
6. Voth D.E., Ballard J.D. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005, 18:247-263.
7. Mani N., Dupuy B. Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc Natl Acad Sci USA 2001, 98:5844-5849.
8. Hundsberger T., Braun V., Weidmann M., et al. Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. Eur J Biochem 1997, 244:735-742.
9. Matamouros S., England P., Dupuy B. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol 2007, 64:1274-1288.
10. Cartman S.T., Kelly M.L., Heeg D., et al. Precise manipulation of the Clostridium difficile chromosome reveals a lack of association between the tcdC genotype and toxin production. Appl Environ Microbiol 2012, 78:4683-4690.
11. Bakker D., Smits W.K., Kuijper E.J., et al. TcdC does not significantly repress toxin expression in Clostridium difficile 630DeltaErm. PLoS One 2012, 7:e43247.
12. Tan K.S., Wee B.Y., Song K.P. Evidence for holin function of tcdE gene in the pathogenicity of Clostridium difficile. JMed Microbiol 2001, 50:613-619.
13. Dineen S.S., Villapakkam A.C., Nordman J.T., et al. Repression of Clostridium difficile toxin gene expression by CodY. Mol Microbiol 2007, 66:206-219.
14. Antunes A., Martin-Verstraete I., Dupuy B. CcpA-mediated repression of Clostridium difficile toxin gene expression. Mol Microbiol 2011, 79:882-899.
15. Dingle K.E., Elliott B., Robinson E., et al. Evolutionary history of the Clostridium difficile pathogenicity locus. Genome Biol Evol 2014, 6:36-52.
16. Hunt J.J., Ballard J.D. Variations in virulence and molecular biology among emerging strains of Clostridium difficile. Microbiol Mol Biol Rev 2013, 77:567-581.
17. Papatheodorou P., Zamboglou C., Genisyuerek S., et al. Clostridial glucosylating toxins enter cells via clathrin-mediated endocytosis. PLoS One 2010, 5:e10673.
18. Zhang Z., Park M., Tam J., et al. Translocation domain mutations affecting cellular toxicity identify the Clostridium difficile toxin B pore. Proc Natl Acad Sci USA 2014, 111:3721-3726.
19. Egerer M., Giesemann T., Jank T., et al. Auto-catalytic cleavage of Clostridium difficile toxins A and B depends on cysteine protease activity. JBiol Chem 2007, 282:25314-25321.
20. Pruitt R.N., Chagot B., Cover M., et al. Structure-function analysis of inositol hexakisphosphate-induced autoprocessing in Clostridium difficile toxin A. JBiol Chem 2009, 284:21934-21940.
21. Kuehne S.A., Cartman S.T., Heap J.T., et al. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010, 467:711-713.
22. Kuehne S.A., Cartman S.T., Minton N.P. Both, toxin A and toxin B, are important in Clostridium difficile infection. Gut Microbes 2011, 2:252-255.
23. Lyras D., O'Connor J.R., Howarth P.M., et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009, 458:1176-1179.
24. Loo V.G., Bourgault A.M., Poirier L., et al. Host and pathogen factors for Clostridium difficile infection and colonization. NEngl J Med 2011, 365:1693-1703.
25. Steele J., Mukherjee J., Parry N., et al. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. JInfect Dis 2013, 207:323-330.
26. Gerding D.N., Johnson S., Rupnik M., et al. Clostridium difficile binary toxin CDT: mechanism, epidemiology, and potential clinical importance. Gut Microbes 2014, 5:15-27.
27. Papatheodorou P., Carette J.E., Bell G.W., et al. Lipolysis-stimulated lipoprotein receptor (LSR) is the host receptor for the binary toxin Clostridium difficile transferase (CDT). Proc Natl Acad Sci USA 2011, 108:16422-16427.
28. Schwan C., Stecher B., Tzivelekidis T., et al. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog 2009, 5:e1000626.
29. Schwan C., Kruppke A.S., Nolke T., et al. Clostridium difficile toxin CDT hijacks microtubule organization and reroutes vesicle traffic to increase pathogen adherence. Proc Natl Acad Sci USA 2014, 111:2313-2318.
30. Fagan R.P., Albesa-Jove D., Qazi O., et al. Structural insights into the molecular organization of the S-layer from Clostridium difficile. Mol Microbiol 2009, 71:1308-1322.
31. Vedantam G., Clark A., Chu M., et al. Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response. Gut Microbes 2012, 3:121-134.
32. Madan R., Jr W.A. Immune responses to Clostridium difficile infection. Trends Mol Med 2012, 18:658-666.
33. Rupnik M., Wilcox M.H., Gerding D.N. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009, 7:526-536.
34. Dingle K.E., Didelot X., Ansari M.A., et al. Recombinational switching of the Clostridium difficile S-layer and a novel glycosylation gene cluster revealed by large-scale whole-genome sequencing. JInfect Dis 2013, 207:675-686.
35. Walker A.W., Lawley T.D. Therapeutic modulation of intestinal dysbiosis. Pharmacol Res 2013, 69:75-86.
36. Britton R.A., Young V.B. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology 2014, 146:1547-1553.
37. Theriot C.M., Young V.B. Microbial and metabolic interactions between the gastrointestinal tract and infection. Gut Microbes 2014, 5:86-95.
38. Peterfreund G.L., Vandivier L.E., Sinha R., et al. Succession in the gut microbiome following antibiotic and antibody therapies for Clostridium difficile. PLoS One 2012, 7:e46966.
39. Chang J.Y., Antonopoulos D.A., Kalra A., et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. JInfect Dis 2008, 197:435-438.
40. Littman D.R., Pamer E.G. Role of the commensal microbiota in normal and pathogenic host immune responses. Cell Host Microbe 2011, 10:311-323.
41. Solomon K. The host immune response to Clostridium difficile infection. Ther Adv Infect Dis 2013, 1:19-35.
42. Lawley T.D., Clare S., Walker A.W., et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 2012, 8:e1002995.
43. Lawley T.D., Clare S., Walker A.W., et al. Antibiotic treatment of Clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect Immun 2009, 77:3661-3669.
44. Maslowski K.M., Mackay C.R. Diet, gut microbiota and immune responses. Nat Immunol 2011, 12:5-9.
45. Theriot C.M., Koenigsknecht M.J., Carlson P.E., et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun 2014, 5:3114.
46. Ng K.M., Ferreyra J.A., Higginbottom S.K., et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 2013, 502:96-99.
47. Dodin M., Katz D.E. Faecal microbiota transplantation for Clostridium difficile infection. Int J Clin Pract 2014, 68:363-368.
48. Borody T.J., Brandt L.J., Paramsothy S. Therapeutic faecal microbiota transplantation: current status and future developments. Curr Opin Gastroenterol 2014, 30:97-105.
49. Kelly C.P., Kyne L. The host immune response to Clostridium difficile. JMed Microbiol 2011, 60:1070-1079.
50. Shen A., Lupardus P.J., Gersch M.M., et al. Defining an allosteric circuit in the cysteine protease domain of Clostridium difficile toxins. Nat Struct Mol Biol 2011, 18:364-371.
51. Branka J.E., Vallette G., Jarry A., et al. Early functional effects of Clostridium difficile toxin A on human colonocytes. Gastroenterology 1997, 112:1887-1894.
52. Corfield A.P., Myerscough N., Longman R., et al. Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease. Gut 2000, 47:589-594.
53. Hing T.C., Ho S., Shih D.Q., et al. The antimicrobial peptide cathelicidin modulates Clostridium difficile-associated colitis and toxin A-mediated enteritis in mice. Gut 2013, 62:1295-1305.
54. Giesemann T., Guttenberg G., Aktories K. Human alpha-defensins inhibit Clostridium difficile toxin B. Gastroenterology 2008, 134:2049-2058.
55. Mahida Y.R., Makh S., Hyde S., et al. Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment. Gut 1996, 38:337-347.
56. Kelly C.P., Becker S., Linevsky J.K., et al. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. JClin Invest 1994, 93:1257-1265.
57. Mahida Y.R., Galvin A., Makh S., et al. Effect of Clostridium difficile toxin A on human colonic lamina propria cells: early loss of macrophages followed by T-cell apoptosis. Infect Immun 1998, 66:5462-5469.
58. Mykoniatis A., Anton P.M., Wlk M., et al. Leptin mediates Clostridium difficile toxin A-induced enteritis in mice. Gastroenterology 2003, 124:683-691.
59. Ishida Y., Maegawa T., Kondo T., et al. Essential involvement of IFN-gamma in Clostridium difficile toxin A-induced enteritis. JImmunol 2004, 172:3018-3025.
60. Ryan A., Lynch M., Smith S.M., et al. Arole for TLR4 in Clostridium difficile infection and the recognition of surface layer proteins. PLoS Pathog 2011, 7:e1002076.
61. Jarchum I., Liu M., Lipuma L., et al. Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis. Infect Immun 2011, 79:1498-1503.
62. Hasegawa M., Yamazaki T., Kamada N., et al. Nucleotide-binding oligomerization domain 1 mediates recognition of Clostridium difficile and induces neutrophil recruitment and protection against the pathogen. JImmunol 2011, 186:4872-4880.
63. Ng J., Hirota S.A., Gross O., et al. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology 2010, 139:542-552. 52.e1-3.
64. Savidge T.C., Urvil P., Oezguen N., et al. Host S-nitrosylation inhibits clostridial small molecule-activated glucosylating toxins. Nat Med 2011, 17:1136-1141.
65. Peniche A.G., Savidge T.C., Dann S.M. Recent insights into Clostridium difficile pathogenesis. Curr Opin Infect Dis 2013, 26:447-453.
66. Meyer G.K., Neetz A., Brandes G., et al. Clostridium difficile toxins A and B directly stimulate human mast cells. Infect Immun 2007, 75:3868-3876.
67. Steele J., Chen K., Sun X., et al. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. JInfect Dis 2012, 205:384-391.
68. Bianco M., Fedele G., Quattrini A., et al. Immunomodulatory activities of surface-layer proteins obtained from epidemic and hypervirulent Clostridium difficile strains. JMed Microbiol 2011, 60:1162-1167.
69. Wullt M., Noren T., Ljungh A., et al. IgG antibody response to toxins A and B in patients with Clostridium difficile infection. Clin Vaccine Immunol 2012, 19:1552-1554.
70. Aronsson B., Granstrom M., Mollby R., et al. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection 1985, 13:97-101.
71. Monaghan T.M., Robins A., Knox A., et al. Circulating antibody and memory B-Cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis. PLoS One 2013, 8:e74452.
72. Leav B.A., Blair B., Leney M., et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010, 28:965-969.
73. Humphreys D.P., Wilcox M.H. Antibodies for the treatment of Clostridium difficile infection. Clin Vaccine Immunol 2014, 21(7):913-923.
74. Lishman A.H., Al-Jumaili I.J., Record C.O. Antitoxin production in antibiotic-associated colitis?. JClin Pathol 1981, 34:414-415.
75. Bacon A.E., Fekety R. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea. Diagn Microbiol Infect Dis 1994, 18:205-209.
76. Nakamura S., Mikawa M., Nakashio S., et al. Isolation of Clostridium difficile from the feces and the antibody in sera of young and elderly adults. Microbiol Immunol 1981, 25:345-351.
77. Kovaiou R.D., Herndler-Brandstetter D., Grubeck-Loebenstein B. Age-related changes in immunity: implications for vaccination in the elderly. Expert Rev Mol Med 2007, 9:1-17.
78. Leuzzi R., Adamo R., Scarselli M. Vaccines against Clostridium difficile. Hum Vaccin Immunother 2014, 10:1466-1477.
79. Lowy I., Molrine D.C., Leav B.A., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. NEngl J Med 2010, 362:197-205.
80. Barra-Carrasco J., Paredes-Sabja D. Clostridium difficile spores: a major threat to the hospital environment. Future Microbiol 2014, 9:475-486.
81. Deakin L.J., Clare S., Fagan R.P., et al. The Clostridium difficile spo0A gene is a persistence and transmission factor. Infect Immun 2012, 80:2704-2711.
82. Baines S.D., O'Connor R., Saxton K., et al. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. JAntimicrob Chemother 2009, 63:520-525.
83. Paredes-Sabja D., Cofre-Araneda G., Brito-Silva C., et al. Clostridium difficile spore-macrophage interactions: spore survival. PLoS One 2012, 7:e43635.
84. Paredes-Sabja D., Sarker M.R. Interactions between Clostridium perfringens spores and Raw 264.7 macrophages. Anaerobe 2012, 18:148-156.
85. Ali S., Moore G., Wilson A.P. Spread and persistence of Clostridium difficile spores during and after cleaning with sporicidal disinfectants. JHosp Infect 2011, 79:97-98.
86. Paredes-Sabja D., Shen A., Sorg J.A. Clostridium difficile spore biology: sporulation, germination, and spore structural proteins. Trends Microbiol 2014, 22(7):406-416.
87. Sorg J.A., Sonenshein A.L. Bile salts and glycine as cogerminants for Clostridium difficile spores. JBacteriol 2008, 190:2505-2512.
88. Wheeldon L.J., Worthington T., Lambert P.A. Histidine acts as a co-germinant with glycine and taurocholate for Clostridium difficile spores. JAppl Microbiol 2011, 110(4):987-994.
89. Howerton A., Ramirez N., Abel-Santos E. Mapping interactions between germinants and Clostridium difficile spores. JBacteriol 2011, 193:274-282.
90. Francis M.B., Allen C.A., Shrestha R., et al. Bile acid recognition by the Clostridium difficile germinant receptor, CspC, is important for establishing infection. PLoS Pathog 2013, 9:e1003356.
91. Nagarajan K., Loh K.C. Molecular biology-based methods for quantification of bacteria in mixed culture: perspectives and limitations. Appl Microbiol Biotechnol 2014, 98(16):6907-6919.
92. Solomon K.V., Haitjema C.H., Thompson D.A., et al. Extracting data from the muck: deriving biological insight from complex microbial communities and non-model organisms with next generation sequencing. Curr Opin Biotechnol 2014, 28C:103-110.
93. Cho S.W., Kim S., Kim J.M., et al. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 2013, 31:230-232.
94. Buffie C.G., Pamer E.G. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol 2013, 13:790-801.
95. Leushacke M., Barker N. Exvivo culture of the intestinal epithelium: strategies and applications. Gut 2014, 63:1345-1354.
96. Foulke-Abel J., In J., Kovbasnjuk O., et al. Human enteroids as an ex-vivo model of host-pathogen interactions in the gastrointestinal tract. Exp Biol Med (Maywood) 2014, 239(9):1124-1134.